A federal judge's ruling essentially blocks compound pharmacies from selling less-expensive, unapproved versions of Ozempic ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Novo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while larger, federally licensed compounders have until May 22 to keep producing ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Hims & Hers (HIMS) stock in focus as a U.S. court denies injunction to continue making cheap versions of Novo Nordisk's (NVO) ...

Zepbound (tirzepatide) is a weekly injectable weight-loss medication. It can be purchased online or in person with a valid ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

SIGNIFICANT EVENTS DURING 1 JANUARY - 31 MARCH 2025Iconovo and Lonza have entered a collaboration to develop spray-dried formulations of an intranasal biologic drug for Iconovo's proprietary intranasa ...